Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976391 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 586
- Enrollment target
NCT00976391 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 586 participants.
The verdict
NCT00976391, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 586 participants
- Enrollment target
Study Summary
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
Interventions
- BIOLOGICAL albiglutide + insulin glargine
- DRUG insulin glargine + preprandial lispro insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976391
The ClinicalTrials.gov registry entry for NCT00976391 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 586 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which albiglutide + insulin glargine is the first listed.
NCT00976391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976391 about?
NCT00976391 is a clinical study titled "A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine". This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
What is the current status of trial NCT00976391?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 2009-09. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00976391?
The interventions under investigation include: albiglutide + insulin glargine (BIOLOGICAL), insulin glargine + preprandial lispro insulin (DRUG).
Who is sponsoring clinical trial NCT00976391?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.